The present invention falls within the field of medical technology, and in particular relates to a halo-allylamine compound as shown in formula (I), and a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1, R2, R3, R4, R5, R6, L1, Cy1 and R7 are as defined in the description； and the present invention also relates to a pharmaceutical preparation and a pharmaceutical composition comprising the compounds, and the use of same in preventing and/or treating diseases related to or mediated by the SSAO/VAP-1 protein.本發明屬於醫藥技術領域，具體涉及式I所示的鹵代烯丙基胺類化合物，其藥學上可接受的鹽，酯或它們的立體異構體，R1、R2、R3、R4、R5、R6、L1、Cy1、R7如說明書中所定義；本發明還涉及包含這些化合物的藥物製劑、藥物組合物，及其在預防和/或治療與SSAO/VAP-1蛋白有關或由SSAO/VAP-1蛋白介導的疾病的用途。
